NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.03, $0.06 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $156 million versus the consensus estimate of $152.54 million.

GUIDANCE:

NeoGenomics sees FY2024 revenue of $650-660 million, versus the consensus of $632.4 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.